Liquid formulations of compounds active at sulfonylurea receptors
The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide.
1. A stable liquid formulation suitable for parenteral administration to a patient, comprising:
10 mM to 50 mM meglumine;
glibenclamide or a pharmaceutically acceptable salt thereof at a concentration of about 0.5 mg/ml to about 1 mg/ml;
a pharmaceutically acceptable infusion solution comprising water, a pharmaceutically acceptable base, and a sugar alcohol;
said liquid formulation has a pH of about pH 9 or higher and is formulated for parenteral administration, wherein the glibenclamide or pharmaceutically acceptable salt thereof has stability and solubility properties such that it does not precipitate out of the solution during or following dilution or when frozen or refrigerated, and
wherein said formulation has stability and solubility properties such that it is stable upon storage for six months, and
wherein said formulation has stability and solubility properties such that it remains free from visible particles upon storage for at least one month.
2. The liquid formulation of claim 1 , wherein said pharmaceutically acceptable liquid infusion solution comprises mannitol.
3. The liquid formulation of claim 1 which has a pH greater than about pH 9.5.
4. The liquid formulation of claim 1 , further comprising a buffer.
5. The liquid formulation of claim 1 , further comprising an alcohol.
6. The liquid formulation of claim 5 , wherein said alcohol is ethyl alcohol.
7. The liquid formulation of claim 1 , further comprising a co-solvent.
8. The liquid formulation of claim 1 , further comprising a surfactant.
9. The liquid formulation of claim 1 , further comprising an alcohol and a co-solvent.
10. The liquid formulation of claim 9 , further comprising a surfactant.
11. The liquid formulation of claim 9 , wherein said alcohol comprises ethyl alcohol.
12. The liquid formulation of claim 9 , wherein said co-solvent comprises a co-solvent selected from propylene glycol and polyalkylene glycol.
13. The liquid formulation of claim 12 , wherein said co-solvent is selected from propylene glycol (PG), polyethylene glycol (PEG), polybutylene glycol, and polypropylene glycol.
14. The liquid formulation of claim 12 , wherein said polyalkylene glycol comprises PEG 300.
15. The liquid formulation of claim 12 , wherein said polyalkylene glycol comprises PEG 400.
16. The liquid formulation of claim 12 , wherein the co-solvent comprises propylene glycol (PG).
17. The liquid formulation of claim 1 , comprising glibenclamide at a concentration of about 1 mg/mL.
18. The liquid formulation of claim 1 , wherein the formulation is formulated for intravenous or intra-arterial delivery and is in a vial suitable for intravenous or intra-arterial delivery.
19. The liquid formulation of claim 1 , wherein the formulation is formulated for injection and is in a vial suitable for injection.
20. The liquid formulation of claim 1 , further comprising propylene glycol (PG) and ethyl alcohol.
21. The liquid formulation of claim 20 , wherein the propylene glycol (PG) and ethyl alcohol are present at a combined weight of at least 50 wt % of a liquid formulation in which the glibenclamide is dissolved.
22. The liquid formulation of claim 1 , further comprising polyethylene glycol and ethyl alcohol.
23. The liquid formulation of claim 22 , wherein the polyethylene glycol and ethyl alcohol are present at a combined weight of at least 50 wt % of a liquid formulation in which the glibenclamide is dissolved.
24. The liquid formulation of claim 1 , wherein the formulation does not contain propylene glycol and polyalkylene glycols.